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Diabetic retinopathy (DR) is an increasingly frequent cause
of blindness across populations; however, the events that
initiate pathophysiology of DR remain elusive. Strong pre-
clinical and clinical evidence suggests that abnormalities in
retinal lipid metabolism caused by diabetes may account for
the origin of this disease. A major arm of lipid metabolism,
de novo biosynthesis, is driven by elevation in available glucose,
a common thread binding all forms of vision loss in diabetes.
Therefore, we hypothesized that aberrant retinal lipid biogen-
esis is an important promoter of early DR. In murine models,
we observed elevations of diabetes-associated retinal de novo
lipogenesis 70% over control levels. This shift was primarily
because of activation of fatty acid synthase (FAS), a rate-
limiting enzyme in the biogenic pathway. Activation of FAS
was driven by canonical glucose-mediated disinhibition of
acetyl-CoA carboxylase, a major upstream regulatory enzyme.
Mutant mice expressing gain-of-function FAS demonstrated
increased vulnerability to DR, whereas those with FAS deletion
in rod photoreceptors maintained preserved visual responses
upon induction of diabetes. Excess retinal de novo lipogenesis
—either because of diabetes or because of FAS gain of function
—was associated with modestly increased levels of palmitate-
containing phosphatidylcholine species in synaptic mem-
branes, a finding with as yet uncertain significance. These
findings implicate glucose-dependent increases in photore-
ceptor de novo lipogenesis in the early pathogenesis of DR,
although the mechanism of deleterious action of this pathway
remains unclear.
Therapy for diabetic retinopathy (DR), a common cause of
visual disability, has evolved greatly over the past 2 decades but
remains ineffective for up to one-third of patients (1). Devel-
opment of new strategies for treatment could be facilitated by
gaining better insight into the pathophysiology of early stage
DR. Abnormalities in retinal lipid metabolism occur early in
the course of diabetes and are therefore attractive candidates
for mediation of mechanisms that eventually result in vision
loss (2).
Retinal lipid abnormalities in diabetes involve both accu-
mulation of deleterious lipids as well as depletion of beneficial
ones. Strategies to correct such abnormalities have the po-
tential to lower risk of vision loss from diabetes. For example,
reversal of cholesterol accumulation in retinas of streptozo-
tocin (STZ)-induced diabetic mice using liver X receptor ag-
onists reduces severity of DR (3). Similarly, lowering of retinal
ceramide levels in diabetes by inhibiting acid sphingomyelinase
activity (4) prevents vascular degeneration (5). Complex and
very long chain polyunsaturated fatty acids (VLC-PUFA),
including docosahexaenoic acid (DHA) and eicosapentaenoic
acid, are disproportionately abundant in the retina compared
with other tissues (6, 7) and are needed to maintain retinal
health but are reduced by diabetes (8, 9). In experimental
models, dietary PUFA replacement reduces DR severity (10),
and in a randomized clinical trial, DHA supplementation was
associated with lower DR severity scores (11).
Photoreceptors, which are increasingly recognized loci of
early DR pathogenesis (12), are particularly susceptible to
perturbations in membrane lipid composition—specifically
because of defects in biosynthetic machinery. For example,
reduction of photoreceptor DHA because of targeted
disruption of the biosynthetic enzyme lysophosphatidic acid
acyltransferase 3 resulted in synaptic dysmorphology and
vision loss (13). Diabetes also reduces DHA biosynthesis
because of downregulation of elongation of VLC fatty acids
protein 4 (ELOVL4), whereas ELOV4 overexpression can
counteract some of the effects of diabetes on the retina (14).
More broadly, lipid derangements because of disruption of
rod photoreceptor fatty acid synthase (FAS)—the enzyme
that catalyzes the committed step of de novo lipogenesis
(15)—causes loss of retinal DHA and VLC-PUFAs, resulting
in a rapid neurodegeneration (16). FAS is a multifunctional
enzyme made up of eight individual catalytic centers, and it
generates palmitate (C16:0) from malonyl-CoA and acetyl-
CoA using NADPH as a cofactor. This pathway is essential
for multiple arms of cellular lipid biosynthesis, including
those responsible for VLC fatty acid production (16).* For correspondence: Rithwick Rajagopal, rajagopalr@wustl.edu; Clay F.
Semenkovich, csemenko@wustl.edu.
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Diabetes is associated with tissue-specific changes in FAS,
which may be root causes of its complications (17, 18). In
macrophages, FAS dysfunction in diabetes results in rear-
rangement of plasma membrane fatty acids, causing
impaired or aberrant cellular signaling (19). In skeletal
muscle, FAS activity and expression are increased in the
setting of insulin resistance, causing increased saturation
index of membrane lipids (20). However, the effects of dia-
betes on this important and elemental lipid biogenesis
pathway in the retina are incompletely described. Here, we
describe studies examining changes to FAS enzyme activity
during diabetes, effects of FAS manipulation on DR pheno-
types, and associated changes to the retinal lipid landscape
during experimental diabetes.
Results
Diabetes is associated with elevated activity of retinal de
novo lipogenesis
To investigate whether flux through de novo lipogenesis is
affected by diabetes, we performed enzyme activity assays in
retinal tissues for FAS. We used three independent models of
diabetes—leptin receptor–deficient mice (db/db), high-fat
diet (HFD)–induced disease, and STZ-induced disease (two
models of type 2 diabetes and one type 1 model)—that are all
associated with progressive retinal dysfunction and dys-
morphology (21–23). After 3 months of exposure to dia-
betes in all models, de novo lipogenesis was assessed by
measuring the incorporation of radiolabeled malonyl-CoA
precursor into palmitate—a reaction uniquely catalyzed by
FAS. The controls for these experiments were healthy lit-
termates of the diseased animals (db/m as controls for db/db,
chow-fed mice for the HFD model, and vehicle-injected mice
in the STZ model). Across all three models, diabetes was
associated with 70% increase in retinal FAS activity
compared with controls (Fig. 1A). Since carbohydrate avail-
ability is an important determinant of biosynthetic flux, we
next performed in vitro assays using short-term retinal ex-
plants derived from 3-month-old healthy WT mice to
determine the effect of glucose on retinal FAS activity.
Exposure of retinal tissue to high glucose (25 mM D-glucose)
for 6 h caused an 60% increase in FAS activity compared
with an osmotically balanced low glucose control medium
(5 mM D-glucose + 20 mM L-glucose) (Fig. 1B). These in-
creases were similar to the effects of insulin (100 ng/ml),
which is known to positively modulate FAS activity through
allosteric effects (Fig. 1B).
To determine whether diabetes caused elevated FAS activity
via changes in Fasn mRNA or protein levels, we performed
Western blotting and quantitative PCR in retinal tissues. FAS
protein levels were unchanged between healthy retinas or
those exposed to one of three forms of experimental diabetes
(Fig. 1, C and D). Similarly, a 6-h-high glucose pulse or insulin
treatment was not associated with changes in FAS protein
expression or RNA levels in retinal explants (Fig. 1, E–G).
Whereas db/db retinas contained elevated messenger RNA
levels of reactive factors, such as inducible nitric oxide
synthase (INOS) and glial fibrillary acidic protein (GFAP), they
had similar Fasn messenger RNA levels as control db/m tissue
(Fig. 1H).
These results suggest that elevated FAS activity in the retina
during diabetes is caused by a post-translational mechanism
and is responsive to elevated glucose alone. We therefore
examined the properties of acetyl Co-A carboxylase (ACC) in
the diabetic retina since this enzyme is activated by elevated
cellular glucose concentration and acts as an important
regulator of FAS activity by regulating the production of its
necessary substrate, malonyl-CoA. ACC undergoes inhibitory
phosphorylation under conditions of low cellular glucose and
conversely becomes dephosphorylated in high glucose con-
centrations (24). In all three models of experimental diabetes,
we found that ACC was hypophosphorylated relative to
healthy controls, indicative of increased retinal ACC activity in
diabetes (Fig. 1, I and J).
Rod photoreceptors are the predominant source of retinal FAS
activity
We next characterized mice carrying genetic modifications
at the Fasn locus causing loss-of-function (LOF) and gain-of-
function (GOF) phenotypes. In prior studies, we showed that
homozygous deletion of Fasn from the neural retina (Fasnfl/fl;
Chx10-Cre-driven loxp recombination) was associated with a
rapid and early onset neurodegeneration, making this reagent
unsuitable for a long-term DR modeling experiment (16).
Instead, we generated Fasnfl/+;Chx10-Cre+/− (“retina LOF”), as
these heterozygotes do not have any discernible baseline
phenotype. These mice demonstrated a 50% reduction in
FAS protein level in the retina compared with controls,
consistent with our prior observations, and a concomitant
50% reduction in FAS enzyme activity compared with con-
trols (Fig. 2, A–C). Since rod photoreceptors make up >80% of
the cell population in the mouse retina, we also generated
mutants with targeted heterozygous loss of rod FAS using the
i75-Cre transgene (Fasnfl/+;i75-Cre+/−; “rod LOF”) (25). These
mice showed nearly identical losses in FAS protein level and
enzyme activity as retina LOF mice (Fig. 2, A–C), suggesting
that rod photoreceptors are the predominant cellular loci of
retinal de novo lipogenesis. After induction of diabetes with
HFD for 3 months, retina LOF and rod LOF mice have 50%
less FAS enzyme activity than controls on HFD and are on par
with non–diabetes mellitus controls, indicating that both LOF
mutants effectively neutralize the retinal FAS activity gains
caused by chronic HFD (Fig. 2D).
FAS GOF variant
We also characterized baseline retinal phenotypes of mice
with homozygous knock-in of a GOF FAS variant associated
with human intellectual disability and impaired adult neu-
rogenesis (26). This variant, which results in a single amino
acid substitution of tryptophan for arginine at residue 1812
in mice and 1819 in humans (R1812W), demonstrates a
50% increase in enzymatic activity compared with the WT
control in brain tissue (27). Similarly, we found that mice
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Figure 1. Increased rate of de novo lipogenesis in the diabetic retina. A, using a radiolabel incorporation assay that interrogates fatty acid synthase (FAS)
function, rates of de novo lipogenesis were measured from whole retinal extracts derived from animals after 3 months of exposure to DM in three different
models (high-fat diet feeding, HFD; leptin receptor mutants, db/db; or streptozotocin-induced, STZ) or from healthy littermates. B, FAS activity in retinal
explants derived from 3-month-old WT animals and cultured for 6 h in control media (5 mM D-glucose + 20 mM L-glucose), high glucose (25 mM D-glucose),
or high insulin (5 mM D-glucose + 20 mM L-glucose + 100 ng/ml insulin). C and D, Western blots and quantification for FAS or a loading control (Akt) from
retinal extracts derived from animals with diabetes (db/db; STZ injected) or their healthy controls (db/m; vehicle treated). E and F, Western blots and
quantification for FAS or Akt from retinal explant cultures in control, high glucose, or high insulin conditions for 6 h. G, quantitative polymerase chain
reaction for Fasn from retinal explants cultured for 6 h in control media or media containing either high glucose or high insulin. H, quantitative polymerase
chain reaction from retinal extracts of db/db mice or healthy db/m controls for the gene targets indicated. I and J, Western blots and quantification for
phosphorylated acetyl co-A carboxylase (ACC) or a total ACC from retinal extracts derived from animals with diabetes (db/db; HFD; STZ injected) or their
healthy controls (db/m; chow fed; vehicle treated). Data represent mean with interquartile range (box) and range (whiskers) and were analyzed by Student’s t
test (A, D, G, and J) or one-way ANOVA (B, F, and H). *p < 0.05, **p < 0.01, and ***p < 0.001. DM, diabetes mellitus.
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carrying this variant have 50% elevation in retinal FAS
activity compared with controls but with no associated in-
crease in protein expression (Fig. 2, A–C). Interestingly, the
GOF mice showed no additive increase in enzyme activity
after induction of diabetes compared with controls (Fig. 2D).
Even at 12 months of age, we did not observe any degener-
ative changes or other gross morphological phenotype in
retina LOF, rod LOF, or GOF mutants compared with con-
trols (Fig. 2, E and F).
Effects of FAS reduction in rods on DR phenotypes
We next assessed whether DR phenotypes are affected by
FAS rod LOF mice. After HFD induction, we performed
electroretinography (ERG) to assess scotopic oscillatory
potential (OP) characteristics—features that are associated
with early retinal damage in human diabetes and features
that our group has shown to precede the onset of typical
vascular lesions in this mouse model (23). Whereas HFD for
6 months causes increased latency of OP timing across all
four major peaks and loss of OP amplitudes compared with
nondiabetic littermates in control animals, such changes
were not seen in mice with FAS rod LOF (Fig. 3, A–C).
Similar to our previous observations, HFD does not impact
scotopic a-wave or b-wave amplitudes, and background FAS
rod LOF does not change this feature of the ERG (Fig. 3, D
and E). These results argue that diabetes-specific ERG defi-
cits in HFD-fed mice are reversible by partial loss of FAS
activity. To confirm that the protective changes extended
beyond ERG effects, we performed quantitative PCR for gene
products that are known to react to diabetes-induced stress
in the retina. Whereas HFD-fed mice had elevated
messenger RNA levels of vascular endothelial growth factor-
a, intercellular adhesion molecule 1, INOS and GFAP, rod
LOF mice on HFD had no such elevations compared with
rod LOF on chow diet or compared with control mice on
chow diet (Fig. 3F).
Effects of FAS GOF on retinal function in diabetes
Using mice homozygous for the FAS R1812W variant, we
induced diabetes by HFD and measured retinal function by
scotopic ERG. As previously observed, we found that HFD
was associated with loss of OP amplitudes, without effects on
a-wave or b-wave amplitudes, and only at 6 months of
exposure to disease but not at an earlier time point (Fig. 4,
A–F). FAS GOF on HFD showed no changes in this pattern
of disease expression and did not impact the severity of OP
Figure 2. Manipulation of retinal FAS activity using loss-of-function and gain-of-function approaches. A and B, Western blots and quantification for
FAS from retinal extracts of C57Bl/6J mice (WT), Fasnfl/+;Chx10-Cre+/− mice (retina LOF), FasnR1812W/R1812W mice (GOF), or Fasnfl/+; i75-Cre+/− mice (rod LOF). C,
FAS activity from retinal extracts of WT, retina LOF, rod LOF, or GOF mice. D, retinal FAS activity from WT, retina LOF, rod LOF, or GOF mice with 3 months of
exposure to high-fat diet–induced DM compared with healthy WT mice (non-DM). E, representative hematoxylin and eosin–stained paraffin cross sections
of retinas from control, retina LOF, and GOF mice with the indicated genotypes and (F) quantification of retinal thicknesses as measured as distances from
the nerve fiber layer (NFL) to retinal pigment epithelium (RPE). B–D, data represent mean with interquartile range (box) and range (whiskers) and were
analyzed by one-way ANOVA. F, data represent mean with SEM and were analyzed by two-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001. DM, diabetes mellitus; FAS, fatty acid synthase; GOF, gain of function; LOF, loss of function.
Fatty acid synthase drives early diabetic retinopathy
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amplitude loss at 6 months compared with controls (Fig. 4F).
However, while FAS GOF showed similar delays in OP
timing after 6 months of HFD exposure compared with
controls, we also observed such delays after 3 months of
HFD exposure when control animals had not yet manifested
the phenotype (Fig. 4, G and H). FAS GOF mice on chow diet
showed no difference in ERG characteristics compared with
WT controls on chow diet at any age tested (up to
12 months). Together, these results suggest that elevated
FAS activity alone is insufficient to reproduce the effects of
diabetes on retinal function loss, but that it does accelerate
such effects.
Figure 3. Effects of FAS haploinsufficiency in rod photoreceptors on diabetes-induced electroretinographic deficits and reactive gene expression.
A, representative oscillatory potential (OP) waveforms from scotopic electroretinograms after a 0.25 cd⋅s/m2 white flash showing four major peaks (OP 1–4)
in control animals (Fasn+/+; i75-Cre+/−) or rod LOF (Fasnfl/+; i75-Cre+/−) mice that were subjected to high-fat diet (HFD)–induced diabetes mellitus (DM) or
standard chow feeding (non-DM). B, luminance-response curves of normalized scotopic OP amplitudes in control mice or mice with FAS rod LOF, comparing
HFD-induced DM or non-DM (chow-fed) conditions. C, scotopic OP implicit times (latencies) after a 0.25 cd⋅s/m2 white flash for each major peak in non-DM
mice or those with HFD-induced DM. D, scotopic a-wave luminance-response curves and (E) b-wave luminance response curves from the indicated groups,
represented as normalized ratios of the maximal flash amplitude after a 7.863 cd⋅s/m2 stimulus. F, quantitative polymerase chain reaction for the gene
targets indicated from retinal extracts of mice after 12 months of exposure to HFD-induced DM or under healthy chow-fed condition (non-DM) controls. B,
D, and E, data represent mean with SEM and were analyzed by two-way ANOVA. C and F, data represent mean with interquartile range (box) and range
(whiskers) and were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. In panel B, *p < 0.05 comparing “control NON
DM” to “control DM”; ††p < 0.01 comparing “control DM” to “Fas Rod Het DM.” FAS, fatty acid synthase; LOF, loss of function.
Fatty acid synthase drives early diabetic retinopathy
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Figure 4. Effects of FAS gain-of-function on retinal function during the course of high-fat diet–induced diabetes. Scotopic a-wave luminance-
response curves, represented as normalized ratios of the maximal flash amplitude after a 7.863 cd⋅s/m2 stimulus, at 3 months (A) and 6 months (B) af-
ter DM induction in control mice or mice carrying the FAS R1812W gain-of-function (GOF) polymorphism. Normalized b-wave luminance-response curves at
3 months (C) and 6 months (D) after DM induction in control or GOF mice. Luminance-response curves of normalized scotopic oscillatory potential (OP)
amplitudes at 3 months (E) and 6 months (F) after DM induction in control and GOF mice. Scotopic OP implicit times (latencies) after a 0.25 cd⋅s/m2 white
flash for each major peak in non-DM mice or those with HFD-induced DM after 3 months of exposure (G) or 6 months of exposure (H) to experimental diet,
and with or without FAS GOF. A–F, data represent mean with SEM and were analyzed by two-way ANOVA. G and H, data represent mean with interquartile
range (box) and range (whiskers) and were analyzed by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. In panel F, *p < 0.05,
****p < 0.0001 comparing “WT NON DM” to “WT DM”; ††††p < 0.0001 comparing “FAS R1812W NON DM” to “FAS R1812W DM.” DM, diabetes mellitus; FAS,
fatty acid synthase.
Fatty acid synthase drives early diabetic retinopathy
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Effects of diabetes and elevated FAS activity on retinal
synaptic lipids
Our observations with FAS mutants on DR phenotypes in
mice suggest that abnormally elevated activity of this enzyme
directly contributes to the pathogenesis of vision loss in dia-
betes. To explore a potential mechanism, we performed lipid
surveys of isolated retinal synaptic membranes, as these
structures are highly susceptible to changes in retinal FAS
activity (16). Among sucrose gradient fractions enriched for
retinal synaptic membranes, we observed an increase in
phosphatidylcholines (PCs) containing saturated fatty acids
(SFAs)—specifically those with C16:0—in diabetic db/db mice
compared with nondiabetic db/m littermate controls (Table 1).
In addition, diabetic samples had lower relative content of PCs
with unsaturated fatty acids and long alkyl chains (>20 C)
compared with nondiabetic controls, consistent with obser-
vations performed by others using whole-retina extracts. After
performing the same analysis in samples from FAS GOF mice
(nondiabetic) and comparing to WT control tissue, we found
that excess FAS activity caused a 4% elevation of retinal syn-
aptic dipalmitoyl-PC (DPPC, PC 16:0/16:0) (Table 2). Of note,
FAS GOF mice did not have any relative depletion of PUFA-
containing PCs and, on the contrary, had elevated levels of
PC 22:6/22:6 compared with controls (Table 2). The changes
we observed in synaptic membrane content in diabetic mice
were specific, since no observed differences were seen among
lyso-PCs (Table 3). In FAS GOF, we observed a moderate
increase in lyso-PCs 32:6 compared with WT controls
(Table 4). We observed no changes in phosphatidylethanol-
amines (PEs) over controls in tissues from diabetic mice
(Table 5) or FAS GOF mice (Table 6).
Discussion
Vision loss from DR commonly occurs because of a pro-
gressive vasculopathy that has well-defined ophthalmoscopic
characteristics (28). However, damage to the retina in diabetes
occurs long before the onset of such lesions and likely involves
numerous nonvascular cell types of the retina, notably pho-
toreceptors. In preclinical models, inactivating mutations in
components of the rod visual cycle (including Rho, RPE65, and
Gnat1), pharmacologic blockade of RPE65, or prolonged visual
sensory deprivation are all associated with reduction in DR
severity or even outright prevention of any detectable DR
(29–32). Taken together with the long-recognized unique
metabolic demands of photoreceptors (33), these observations
strongly implicate perturbations in photoreceptor and/or vi-
sual cycle metabolism as a key initiating event in the patho-
genesis of DR. The current study provides insight into a
putative role for an arm of photoreceptor metabolism—that of
de novo lipogenesis regulated by FAS—as one such molecular
pathway altered by diabetes. In type 1 and type 2 models of
diabetes, elevated retinal FAS activity was associated with
hyperglycemia and disinhibition of ACC, a proximal regulatory
enzyme. Nearly, all the excess de novo lipogenic activities in
Table 1
Changes in normalized retinal synaptic membrane PC content associated with experimental diabetes
PC species Control (95% confidence interval); n = 6 Diabetes (95% confidence interval); n = 6 p
14:0/16:1 0.061 (0.057–0.065) 0.069 (0.067–0.071) 0.004
14:0/16:0 0.043 (0.040–0.046) 0.041 (0.039–0.044) 0.425
p16:0/16:1 0.006 (0.005–0.007) 0.007 (0.007–0.008) 0.012
a16:0/16:1 0.018 (0.016–0.019) 0.022 (0.021–0.024) 0.002
16:1/16:1 0.011 (0.010–0.013) 0.014 (0.013–0.015) 0.007
16:0/16:1 0.157 (0.152–0.162) 0.163 (0.159–0.167) 0.109
16:0/16:0 1.012 (0.981–1.043) 1.015 (0.982–1.048) 0.896
p16:0/18:1 0.026 (0.024–0.028) 0.034 (0.032–0.037) 0.0006
a16:0/18:1 0.022 (0.022–0.023) 0.022 (0.021–0.023) 0.996
16:1/18:2 0.012 (0.011–0.013) 0.015 (0.013–0.016) 0.009
16:0/18:2; 16:1/18:1 0.104 (0.098–0.109) 0.124 (0.113–0.134) 0.007
16:0/18:1 0.354 (0.348–0.360) 0.356 (0.347–0.365) 0.764
p16:0/20:4 0.020 (0.019–0.022) 0.022 (0.020–0.023) 0.401
a16:0/20:4 0.016 (0.015–0.018) 0.016 (0.014–0.018) 0.771
a18:0/18:1 0.019 (0.017–0.020) 0.017 (0.015–0.019) 0.166
16:0/20:4 0.109 (0.103–0.116) 0.102 (0.099–0.105) 0.075
16:0/20:3; 18:1/18:2 0.055 (0.053–0.057) 0.058 (0.054–0.062) 0.187
18:1/18:1; 18:0/18:2 0.128 (0.124–0.131) 0.122 (0.119–0.125) 0.030
16:0/22:6 0.509 (0.485–0.532) 0.472 (0.459–0.486) 0.025
18:0/18:1 0.427 (0.395–0.458) 0.428 (0.423–0.432) 0.953
p18:0/20:4 0.014 (0.013–0.016) 0.015 (0.014–0.015) 0.621
a18:0/20:4 0.012 (0.010–0.014) 0.013 (0.012–0.014) 0.746
18:1/20:4; 16:0/22:5 0.102 (0.099–0.106) 0.097 (0.095–0.099) 0.046
18:0/20:4 0.163 (0.149–0.176) 0.149 (0.145–0.153) 0.092
18:1/22:6 0.061 (0.059–0.062) 0.061 (0.058–0.065) 0.771
18:0/22:6 0.658 (0.594–0.721) 0.666 (0.638–0.694) 0.809
18:0/22:5 0.103 (0.094–0.113) 0.106 (0.102–0.110) 0.653
18:0/22:4 0.335 (0.305–0.364) 0.335 (0.322–0.348) 0.977
42:10 0.174 (0.163–0.185) 0.178 (0.167–0.189) 0.642
42:4 0.008 (0.007–0.009) 0.006 (0.005–0.007) 0.026
22:6/22:6 0.151 (0.145–0.157) 0.153 (0.137–0.168) 0.856
22:6/32:6 0.027 (0.025–0.028) 0.023 (0.020–0.026) 0.050
22:6/34:6 0.027 (0.025–0.029) 0.021 (0.018–0.025) 0.019
22:5/24:6 0.018 (0.016–0.020) 0.014 (0.012–0.015) 0.006
22:6/34:6 0.003 (0.003–0.004) 0.002 (0.002–0.003) 0.003
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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the diabetic retina were attributed to rod FAS, whereas tar-
geted loss of FAS in rods mitigated DR-associated scotopic OP
amplitude reductions and implicit time delays. Furthermore,
we linked elevated FAS activity to increased palmitate content
within retinal synaptic membranes, similar to changes seen
with diabetes alone.
Our observations are consistent with those of others
studying lipid dysmetabolism in the diabetic retina, but some
important distinctions deserve attention. Similar to Busik
et al., we found that retinal membranes from diabetic mice
were relatively depleted of DHA-containing phospholipids
(Table 1). In their studies, retinal DHA reductions in diabetes
were linked to lowered expression of ELOVL2 and ELOVL4,
although the mechanism for suppressed expression of these
factors remains unclear (9). Unlike these investigators, we
found that several SFA-containing species—particularly those
with palmitate (C16:0), such as DPPC—were elevated in DR,
albeit modestly. Whereas prior studies examined changes in
lipid landscapes because of diabetes in whole-retina extracts,
we examined isolated retinal synaptic membranes. This key
difference in methodology likely accounts for the disparity
between our observations compared with a prior study that did
not find changes in SFA content in DR (9).
We chose to study lipid compositions in retinal synaptic
membranes for two reasons. First, in our earlier studies of de
novo lipogenesis in the retina, we found that retinal synaptic
membranes were particularly affected by FAS depletion, which
was associated with reductions in synaptic SFAs and loss of
ribbon architecture (16). In mice with homozygous deletion of
Fasn, we did not observe a depletion of DPPC in whole-retina
extracts. However, after repeating the analysis in gradient
fractions enriched for synaptic membranes, we found marked
Table 2
Changes in normalized retinal synaptic membrane PC content associated with FAS GOF
PC species Control (95% confidence interval); n = 6 FAS GOF (95% confidence interval); n = 6 p
14:0/16:1 0.067 (0.060–0.074) 0.060 (0.057–0.064) 0.129
14:0/16:0 0.039 (0.037–0.041) 0.042 (0.041–0.043) 0.062
p16:0/16:1 0.007 (0.007–0.008) 0.006 (0.006–0.007) 0.062
a16:0/16:1 0.021 (0.019–0.022) 0.020 (0.019–0.021) 0.514
16:1/16:1 0.011 (0.010–0.013) 0.010 (0.008–0.012) 0.171
16:0/16:1 0.155 (0.149–0.162) 0.145 (0.139–0.151) 0.039
16:0/16:0 0.957 (0.946–0.969) 0.998 (0.988–1.010) 0.0003
p16:0/18:1 0.036 (0.033–0.038) 0.033 (0.031–0.035) 0.135
a16:0/18:1 0.023 (0.022–0.025) 0.022 (0.020–0.023) 0.153
16:1/18:2 0.011 (0.010–0.013) 0.011 (0.010–0.012) 0.858
16:0/18:2; 16:1/18:1 0.097 (0.092–0.010) 0.097 (0.092–0.102) 0.994
16:0/18:1 0.345 (0.339–0.351) 0.355 (0.348–0.361) 0.052
p16:0/20:4 0.017 (0.015–0.019) 0.016 (0.015–0.017) 0.351
a16:0/20:4 0.014 (0.012–0.016) 0.014 (0.013–0.015) 0.860
a18:0/18:1 0.017 (0.015–0.018) 0.017 (0.015–0.019) 0.648
16:0/20:4 0.107 (0.097–0.117) 0.093 (0.090–0.097) 0.025
16:0/20:3; 18:1/18:2 0.053 (0.051–0.055) 0.052 (0.050–0.055) 0.529
18:1/18:1; 18:0/18:2 0.113 (0.110–0.116) 0.108 (0.104–0.113) 0.113
p18:0/20:4 0.013 (0.011–0.015) 0.011 (0.010–0.012) 0.104
a18:0/20:4 0.011 (0.009–0.013) 0.011 (0.009–0.013) 0.906
16:0/22:6 0.449 (0.437–0.461) 0.446 (0.418–0.473) 0.827
18:0/18:1 0.414 (0.410–0.419) 0.399 (0.387–0.411) 0.043
18:1/20:4;16:0/22:5 0.091 (0.088–0.094) 0.087 (0.083–0.091) 0.089
18:0/20:4 0.161 (0.149–0.173) 0.142 (0.137–0.147) 0.018
18:1/22:6 0.052 (0.051–0.054) 0.054 (0.052–0.056) 0.114
18:0/22:6 0.583 (0.566–0.600) 0.576 (0.547–0.605) 0.690
18:0/22:5 0.095 (0.092–0.097) 0.090 (0.086–0.095) 0.146
40:4 0.030 (0.029–0.031) 0.029 (0.028–0.030) 0.032
42:10 0.015 (0.014–0.017) 0.013 (0.011–0.015) 0.051
42:4 0.007 (0.007–0.008) 0.007 (0.005–0.008) 0.233
22:6/22:6 0.087 (0.081–0.092) 0.100 (0.094–0.105) 0.006
22:6/32:6 0.018 (0.017–0.019) 0.017 (0.015–0.018) 0.255
22:6/34:6 0.020 (0.018–0.022) 0.018 (0.015–0.021) 0.232
22:5/34:6 0.013 (0.012–0.014) 0.012 (0.009–0.014) 0.314
22:6/36:6 0.003 (0.002–0.003) 0.003 (0.002–0.003) 0.523
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old Fasn+/+ (control) or age-matched FasnR1812W/R1812W (FAS GOF). Groups were compared by two-tailed homoscedastic t test.
Table 3
Changes in normalized retinal synaptic membrane lyso-PC content associated with experimental diabetes
Lyso-PC species Control (95% confidence interval); n = 6 Diabetes (95% confidence interval); n = 6 p
16:0 0.296 (0.221–0.371) 0.850 (−0.216 to 1.916) 0.333
18:1 0.139 (0.103–0.176) 0.391 (−0.085 to 0.867) 0.325
18:0 0.137 (0.106–0.167) 0.392 (−0.087 to 0.870) 0.322
20:0 0.027 (0.021–0.034) 0.075 (−0.019 to 0.169) 0.345
22:6 0.190 (0.144–0.236) 0.538 (−0.131 to 1.207) 0.333
32:6 0.026 (0.024–0.029) 0.071 (−0.017 to 0.159) 0.344
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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reductions in DPPC in animals lacking retinal FAS. Consistent
with these earlier findings, we now found that FAS GOF mice
had elevated levels of DPPC within retinal synapses (Table 2).
Second, our current findings argue that FAS enzyme changes
in diabetes affect ERG function early in the course of disease—
pointing to a potential impact on retinal synaptic health. This
possibility is feasible since lipid content determines membrane
biophysical characteristics, including effects on fluidity and
deformability, which can strongly influence synaptic function
(34). However, because the lipid changes we observed in
synapses were modest, other changes to the retinal lipid
environment—such as alterations in retinal triglyceride con-
tent or to lipid droplet formation in the outer retina—deserve
further study as putative pathogenic mechanisms in FAS GOF
mice.
Importantly, we did not observe a DR-related phenotype (or
any structural or functional phenotype) in FAS GOF mice in
the absence of background diabetes. This result suggests that
overactivity of FAS (on the order of 50% elevation) is insuffi-
cient to produce ERG changes related to DR. Instead, we found
that scotopic OP delays occurred in an accelerated fashion in
FAS GOF mice on HFD compared with WT mice on HFD
(3 months versus 6 months) (Fig. 4). One explanation ac-
counting for these findings is that elevated retinal enzyme ac-
tivity in FAS GOF mice is not high enough to reproduce the
effect of diabetes. Another explanation is that FAS activity in-
creases are one of many diabetes-associated changes in pho-
toreceptors that initiate early DR. Such a model would account
for our finding that retinas from FAS GOF mice had elevated
levels of VLC-PUFA (PC-22:6/22:6 and lyso-PC-32:6, Tables 2
and 4) compared with WT controls, in contrast with tissues
from diabetic mice, which showed relative loss of VLC-PUFA
compared with nondiabetic controls (Table 1). We propose
that combinatorial effects of SFA accumulation because of FAS
overactivity with other retinal membrane modifications in
diabetes, such as loss of VLC-PUFA because of decreased
ELOVL4 or stearyl-CoA desaturase activity, could cause the
necessary lipid pathology needed to initiate DR (Fig. 5).
Although the evidence for a photoreceptor locus of early
pathology in DR is compelling—including some evidence from
patients with inherited retinal degeneration from
photoreceptor-inactivating polymorphisms—the link between
such changes and the eventual development of typical vascular
lesions in DR are unclear (35–37). Data from Busik et al.
suggest that the loss of VLC-PUFA in diabetes may not be at
the level of photoreceptors—even though photoreceptor outer
segments are known to have the highest concentration of these
lipids. Instead, they propose that endothelial PUFA loss,
causing changes in biomechanics of membranes in the vicinity
of claudin-5 complexes, could compromise tight-junction
physiology and lead to barrier dysfunction (14). Another
possibility is that diabetes-induced lipid perturbations at
photoreceptor synapses directly impact neurovascular
coupling (38). These effects could be mediated by changes in
synaptic membrane fluidity and subsequent effects on neuro-
transmission (34). Also possible is that excess retinal SFA
could have deleterious consequences on photoreceptor energy
metabolism, which could in turn impact vascular coupling
Table 4
Changes in normalized retinal synaptic membrane lyso-PC content associated with FAS GOF
Lyso-PC species Control (95% confidence interval); n = 6 FAS GOF (95% confidence interval); n = 6 p
16:0 2.747 (2.178–3.315) 2.807 (2.359–3.255) 0.874
18:1 1.384 (1.098–1.669) 1.300 (1.089–1.511) 0.655
18:0 1.272 (1.003–1.541) 1.380 (1.124–1.635) 0.582
20:0 0.272 (0.216–0.328) 0.226 (0.193–0.259) 0.202
22:6 1.494 (1.197–1.792) 1.487 (1.239–1.736) 0.973
32:6 0.181 (0.100–0.262) 0.349 (0.227–0.470) 0.048
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old Fasn+/+ (control) or age-matched FasnR1812W/R1812W (FAS GOF). Groups were compared by two-tailed homoscedastic t test.
Table 5
Changes in normalized retinal synaptic membrane PE content associated with experimental diabetes
PE species Control (95% confidence interval); n = 6 Diabetes (95% confidence interval); n = 6 p
16:0/16:1 0.017 (0.011–0.023) 0.022 (0.003–0.040) 0.608
16:0/18:2 0.014 (0.005–0.022) 0.012 (0.008–0.016) 0.711
16:0/18:1 0.034 (0.024–0.044) 0.068 (0.055–0.081) 0.002
p16:0/20:4 0.248 (0.176–0.321) 0.338 (0.296–0.381) 0.062
16:0/20:4 0.052 (0.040–0.064) 0.052 (0.036–0.069) 0.984
18:1/18:1 0.032 (0.023–0.042) 0.039 (0.024–0.053) 0.487
18:0/18:1 0.128 (0.090–0.166) 0.099 (0.080–0.118) 0.207
p16:0/22:6 0.399 (0.314–0.483) 0.421 (0.359–0.484) 0.684
p16:0/22:5 0.152 (0.122–0.183) 0.206 (0.179–0.232) 0.026
p18:0/20:4 0.275 (0.227–0.323) 0.420 (0.341–0.498) 0.011
16:0/22:6 0.705 (0.647–0.764) 0.759 (0.637–0.881) 0.456
18:1/20:4 0.149 (0.120–0.177) 0.195 (0.152–0.237) 0.109
18:0/20:3 0.107 (0.082–0.131) 0.067 (0.040–0.094) 0.058
p18:0/22:6 0.525 (0.411–0.639) 0.684 (0.631–0.737) 0.032
18:1/22:6 0.199 (0.166–0.231) 0.238 (0.194–0.281) 0.190
18:0/22:4 0.147 (0.111–0.183) 0.192 (0.139–0.244) 0.197
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an
internal standard. Mice were either 6-month-old db/db (diabetes) or littermate db/m (control). Groups were compared by two-tailed homoscedastic t test.
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responses. For example, in dorsal root ganglia cultures, lip-
otoxicity because of excess SFAs—palmitate in particular—
contributes to neural dysfunction through mitochondrial
damage (39). Alternatively, membrane lipid changes could
directly impact second messenger signaling, for example,
through changes in arachidonic acids or epoxyeicosatrienoic
acids, which are known to mediate neurovascular crosstalk in
the retina (40). Studies designed to monitor small-scale
vascular caliber changes reproducibly show that experi-
mental and clinical diabetes reduces light-stimulated vasodi-
lation in the retina. Lipogenic pathways impacted by diabetes
may account for such changes by directly modifying the
metabolic demands and signaling characteristics of photore-
ceptors. Exploring this possibility could identify a novel target
for early therapeutic intervention in DR.
Experimental procedures
Animals
C57BL/6J mice were obtained from Jackson Laboratories
(stock no. 000664) and were free of rd1 or rd8 mutations.
Leptin receptor mutation-carrying BKS.Cg-Dock7m +/+
Leprdb/J breeding pairs (db/m heterozygotes) were also ob-
tained from Jackson Laboratories (stock no. 000642). F1
progeny were generated with the following expected ratios:
25% homozygous db/db animals, which are spontaneously
diabetic; 50% db/m heterozygous littermates, which are
metabolically healthy; and 25% homozygous m/m mice, which
were routinely discarded. Animals were fed Purina 4043
“chow” (13% kcal from fat, 62% kcal from carbohydrate, and
25% kcal from protein) or Harlan Teklad TD 88137 “HFD”
(42% kcal from fat, 43% kcal from carbohydrate, and 15% kcal
from protein).
In some experiments, STZ was used to induce diabetes in
male mice only, given the known resistance of female C57BL/
6J mice to this drug. To do so, 2-month-old mice were fasted
for 4 h and then given intraperitoneal doses of STZ, 60 mg/kg
dissolved in freshly prepared sodium citrate buffer (pH 4.5) or
citrate buffer alone for controls. The procedure was repeated
every 24 h for a total of five doses. Random blood glucose was
assessed weekly by a portable Glucocard test-strip device
(Arkray USA, Inc) using a drop of blood from tail-vein
puncture, beginning 1 week after STZ dosing. Animals with
glucose values consistently above 300 mg/dl were considered
“diabetic.” Weekly body weight was also monitored, and ani-
mals with >10% reduction in body weight compared with pre-
STZ baseline measurements received regular insulin therapy
(2.5 IU/kg in 0.9% NaCl by intraperitoneal administration
twice a day) to prevent excess catabolism.
Antibodies and quantitative PCR
For Western blotting, we used polyclonal rabbit immuno-
globulin G (IgG) against FAS (catalog no. ab22759; AbCam),
rabbit IgG against ACC phosphorylated at Ser79 (catalog no.
3661; Cell Signaling), rabbit IgG against total ACC (catalog no.
Table 6
Changes in normalized retinal synaptic membrane PE content associated with FAS GOF
PE species Control (95% confidence interval); n = 6 FAS GOF (95% confidence interval); n = 6 p
16:0/16:1 0.038 (0–0.077) 0.019 (0.008–0.029) 0.356
16:0/18:2 0.019 (−0.005 to 0.042) 0.020 (0.008–0.032) 0.915
16:0/18:1 0.105 (−0.029 to 0.238) 0.057 (0.037–0.076) 0.501
p16:0/20:4 0.213 (0.131–0.295) 0.248 (0.192–0.303) 0.506
16:0/20:4 0.037 (0.005–0.068) 0.050 (0.024–0.076) 0.538
18:1/18:1 0.084 (−0.046 to 0.214) 0.016 (0.011–0.022) 0.331
18:0/18:1 0.071 (0.011–0.131) 0.072 (0.046–0.098) 0.970
p16:0/22:6 0.361 (0.218–0.504) 0.336 (0.281–0.391) 0.753
p16:0/22:5 0.144 (0.069–0.219) 0.182 (0.131–0.234) 0.425
p18:0/20:4 0.327 (0.173–0.261) 0.261 (0.196–0.326) 0.455
16:0/22:6 0.583 (0.415–0.751) 0.608 (0.453–0.762) 0.837
18:1/20:4 0.106 (0.086–0.126) 0.197 (0.114–0.279) 0.062
18:0/20:3 0.116 (0.076–0.156) 0.130 (0.090–0.171) 0.633
p18:0/22:6 0.497 (0.265–0.728) 0.546 (0.421–0.671) 0.721
18:1/22:6 0.166 (0.113–0.220) 0.152 (0.137–0.168) 0.631
18:0/22:4 0.210 (0.084–0.337) 0.135 (0.086–0.183) 0.302
Synaptic membranes isolated by sucrose gradient were analyzed by electrospray ionization mass spectrometry. Identified peaks were normalized to input protein content and to an




















Figure 5. A model for FAS activity in photoreceptors in early diabetes.
Diabetes-induced increases in photoreceptor glucose concentration result
in dephosphorylation (disinhibition) of acetyl-CoA carboxylase (ACC), which
in turn increases production of malonyl-CoA—a substrate and allosteric
activator of FAS. FAS-mediated production of palmitate promotes subse-
quent enzymatic reactions that are responsible for production of longer
chain saturated fatty acids (SFAs) and unsaturated fatty acids. Simultaneous
changes in diabetes, such as reduction in docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA), and other very-long chain polyunsaturated
fatty acids (VLC-PUFAs), mediated by suppressed expression of factors such
as elongation of VLC fatty acids protein 4 (ELOVL4) and stearyl-CoA desa-
turase 2 (SCD2), may work in concert to produce membrane changes in the
retina to cause pathology in diabetes. FAS, fatty acid synthase.
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3662; Cell Signaling), and mouse monoclonal IgG1 against
pan-Akt (catalog no. 2920; Cell Signaling).
At the indicated ages, total RNA was extracted from isolated
retinas. After reverse transcription from 0.5 μg of input,
quantitative PCR was performed on the resulting comple-
mentary DNA using the following primer pairs.
Fasn sense 50-GTCGTCTGCCTCCAGAGC-30; Fasn anti-
sense 50-GTTGGCCCAGAACTCCTGTA-30
Vascular endothelial growth factor-a: sense 50-AATG
CTTTCTCCGCTCTGAA-30; antisense 50-GCTTCCTACAG
CACAGCAGA-30
Intercellular adhesion molecule 1: sense 50-AACAGTT-
CACCTGCACGGAC-30; antisense 50-GTCACCGTTGTGAT
CCCTG-30
Inos: sense 50-TGAAGAAAACCCCTTGTGCT-30; anti-
sense 50-TTCTGTGCTGTCCCAGTGAG-30
Gfap: sense 50-TTTCTCGGATCTGGAGGTTG-30; anti-
sense 50-AGATCGCCACCTACAGGAAA-30




Gene expression data were normalized to the mean of two
internal controls—Gapdh and Rpl32.
FAS enzyme activity
Two isolated retinas per animal were homogenized in lysis
buffer and centrifuged as aforementioned. One hundred mi-
croliters of supernatant was added to a buffer containing 0.1 M
potassium phosphate buffer (pH 7.0), 1 mM acetyl-CoA, 1 mM
cold malonyl-CoA, 0.1 μCi 14C-malonyl-CoA (catalog no.
NEC612005UC; PerkinElmer), 1 mM dithiothreitol, 1 mM
EDTA, and 0.5 mM freshly prepared NADPH. This mixture
was incubated in a 37 C agitating bath for 15 min, and re-
actions were then terminated using 7.5 μl of 60% perchloric
acid with immediate vortexing. The resulting cloudy mixture
was treated with 0.25 ml of absolute ethanol. Then, 0.75 ml
petroleum ether was added, and the mixture was agitated and
centrifuged to generate an organic phase containing long-
chain fatty acids. Three such extractions with petroleum
ether were performed, and the pooled organic phase was added
to a scintillation counter to quantitate the radiolabel.
Retinal morphologic assays
Eyes from male and female mice were fixed in 4% para-
formaldehyde at 4 C for 48 h, paraffin embedded, sectioned
into four micron slices, and stained with hematoxylin and
eosin.
ERG
A UTAS BigShot System (LKC Technologies, Inc) was used.
Mice (>5 for each group) were dark-adapted overnight. Under
red-light illumination, animals were anesthetized with keta-
mine (80 mg/kg total body weight) and xylazine (15 mg/kg of
lean body weight). Pupils were dilated with 1% atropine sulfate;
body temperature was maintained at 37 C with a heating pad;
and contact lens electrodes were placed on both eyes along
with appropriate reference and ground electrodes. The stim-
ulus was a 10-μs full-field white-light flash. Repeated trials
were averaged for each luminance, with ten repeats used for
the dimmest flashes and five repeats for the brightest flashes.
Raw data were processed using a MATLAB program (Math-
Works). The amplitude of the a-wave was measured from the
average pretrial baseline to the most negative point of the
average trace, and the b-wave amplitude was measured from
that point to the highest positive point. The log luminance of
the stimulus (log[cd⋅s/m2]) was calculated based on manu-
facturer’s calibrations. OPs were isolated using a digital But-
terworth 100 Hz high-pass filter, and time to peak for each OP
(OP1–OP4) was determined.
Lipid analyses by electrospray ionization mass spectrometry
Two retinas from each animal were freshly isolated, pooled
into 500 μl of 40% methanol, and homogenized in a glass tube
with a Dounce homogenizer. An aliquot of each homogenate
(50 μl) was reserved and diluted in deionized water to 10%
methanol for total protein measurement using Bradford re-
agent. Using the remaining homogenate, an appropriate
amount of 14:0/14:0-PC and 14:0/14:0-PE internal standard
was added before Folch extraction. After extraction, the
organic layer was collected, dried under nitrogen, and recon-
stituted in 200 μl chloroform/methanol (1:1) with 0.1%
NH4OH. A 10-μl aliquot was loop injected into a Thermo
Vantage triple quadrupole mass spectrometer using an Accela
autosampler with 1250 HPLC pump, which delivered a con-
stant flow of 40 μl/min of methanol with 0.1% NH4OH. An-
alyses of PC species were carried out in the positive ion mode
using precursor scan of 184 with a collision energy of 33 eV to
detect the molecular species as the [M + H]+ ions. PE species
were detected as the [M − H]− ions in the negative ion mode
using precursor ion scan of 196 with a collision energy of
50 eV. Quantitation of each individual PC and PE species was
compared with internal standards, and results were normal-
ized to the total protein content of the input.
Isolation of synaptic membranes
To isolate light membrane fractions enriched for synaptic
components, dissected retinas (two from each animal, com-
bined) were lysed in 500 μl of high pH buffer containing
500 mM sodium carbonate (pH 11.0) and protease inhibitors
(Roche), incubated on ice for 30 min, and homogenized by
sonication at 25% amplitude for 20 s with a 50% duty cycle.
Homogenates were adjusted to 800 μl of 45% sucrose and
placed under sucrose layers of 5% (450 μl) and 35% (1 ml).
After centrifugation at 39,000 rpm in an SW-41 rotor (Beck-
man) at 4 C for 16 h, 200-μl fractions were sequentially
collected from top to bottom. Fractions were analyzed by SDS-
PAGE and immunoblotting. The first five fractions were
combined as the light membrane component, and the next five
fractions were considered the heavy membrane component.
Combined fractions were subjected to Folch total lipid
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extraction and analyzed by electrospray ionization mass
spectrometry as described previously.
Statistics
In line graphs, data are expressed as mean ± SEM. In box-
and-whisker plots, data are expressed as median, with the
box showing the limits of the interquartile range, and whiskers
representing maxima and minima. For experiments with two
groups in the independent variable, analyses were performed
using two-tailed t tests without post hoc correction. For ex-
periments with more than two groups in the independent
variable, one-way ANOVA with Bonferroni correction was
used when only one dependent variable was present, and two-
way ANOVA with Bonferroni post tests was used when two or
more dependent variables were present. All calculations were
performed using GraphPad Prism 6.0 software (GraphPad
Software, Inc). In all experiments, * indicates p < 0.05, **p <
0.01, ***p < 0.001, and ****p < 0.0001.
Study approval
Protocols followed the Association for Research in Vision
and Ophthalmology Statement for the Use of Animals and
were approved by Washington University.
Data availability
All datasets included in this article, including synaptic
membrane fatty acid mass spectrometry profiles, will be shared
upon request. Please address all inquiries to Rithwick
Rajagopal.
Acknowledgments—This work was supported by the NIH Grants
EY025269, DK101392, P60 DK20579, and P30EY002687; Research
to Prevent Blindness, New York, NY (Career Development Award
and an Unrestricted Award to the Department of Ophthalmology
and Visual Sciences, Washington University School of Medicine);
the Horncrest Foundation, Saint Louis, MO (Unrestricted Award);
and the Washington University DRC DK020579.
Author contributions—R. R., F.-F. H., and C. F. S. conceptualization;
X. W., M. B., S. J., F.-F. H., and C. F. S. methodology; R. R., B. S.,
S. Z., S. A., X. W., F.-F. H., and C. F. S. formal analysis; R. R., X. W.,
and C. F. S. investigation; M. B. and S. J. resources; R. R., B. S., S. Z.,
S. A., and F.-F. H. data curation; R. R., F.-F. H., and C. F. S. writing–
original draft; R. R., B. S., S. J., and C. F. S. writing–review and
editing; R. R. and C. F. S. funding acquisition.
Funding and additional information—The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
Conflict of interest—The authors declare that they have no conflicts
of interest with the contents of this article.
Abbreviations—The abbreviations used are: ACC, acetyl Co-A
carboxylase; DHA, docosahexaenoic acid; DPPC, dipalmitoyl-PC;
DR, diabetic retinopathy; ERG, electroretinography; FAS, fatty acid
synthase; GFAP, glial fibrillary acidic protein; GOF, gain-of-func-
tion; HFD, high-fat diet; IgG, immunoglobulin G; INOS, inducible
nitric oxide synthase; LOF, loss of function; OP, oscillatory poten-
tial; PC, phosphatidylcholine; PE, phosphatidylethanolamine; SFA,
saturated fatty acid; STZ, streptozotocin; VLC-PUFA, very long
chain polyunsaturated fatty acid.
References
1. Blinder, K. J., Dugel, P. U., Chen, S., Jumper, J. M., Walt, J. G., Hollander,
D. A., and Scott, L. C. (2017) Anti-VEGF treatment of diabetic macular
edema in clinical practice: Effectiveness and patterns of use (ECHO study
report 1). Clin. Ophthalmol. 11, 393–401
2. Busik, J. V. (2021) Lipid metabolism dysregulation in diabetic retinopathy.
J. Lipid Res. 62, 100017
3. Zheng, W., Mast, N., Saadane, A., and Pikuleva, I. A. (2015) Pathways of
cholesterol homeostasis in mouse retina responsive to dietary and phar-
macologic treatments. J. Lipid Res. 56, 81–97
4. Opreanu, M., Tikhonenko, M., Bozack, S., Lydic, T. A., Reid, G. E.,
McSorley, K. M., Sochacki, A., Perez, G. I., Esselman, W. J., Kern, T.,
Kolesnick, R., Grant, M. B., and Busik, J. V. (2011) The unconventional
role of acid sphingomyelinase in regulation of retinal microangiopathy in
diabetic human and animal models. Diabetes 60, 2370–2378
5. Chakravarthy, H., Navitskaya, S., O’Reilly, S., Gallimore, J., Mize, H., Beli,
E., Wang, Q., Kady, N., Huang, C., Blanchard, G. J., Grant, M. B., and
Busik, J. V. (2016) Role of acid sphingomyelinase in shifting the balance
between proinflammatory and reparative bone marrow cells in diabetic
retinopathy. Stem Cells 34, 972–983
6. Agbaga, M. P., Mandal, M. N., and Anderson, R. E. (2010) Retinal very
long-chain PUFAs: New insights from studies on ELOVL4 protein. J.
Lipid Res. 51, 1624–1642
7. Zemski Berry, K. A., Gordon, W. C., Murphy, R. C., and Bazan, N. G.
(2014) Spatial organization of lipids in the human retina and optic nerve
by MALDI imaging mass spectrometry. J. Lipid Res. 55, 504–515
8. Bennett, L. D., Brush, R. S., Chan, M., Lydic, T. A., Reese, K., Reid, G. E.,
Busik, J. V., Elliott, M. H., and Anderson, R. E. (2014) Effect of reduced
retinal VLC-PUFA on rod and cone photoreceptors. Invest. Ophthalmol.
Vis. Sci. 55, 3150–3157
9. Tikhonenko, M., Lydic, T. A., Wang, Y., Chen, W., Opreanu, M.,
Sochacki, A., McSorley, K. M., Renis, R. L., Kern, T., Jump, D. B., Reid, G.
E., and Busik, J. V. (2010) Remodeling of retinal fatty acids in an animal
model of diabetes: A decrease in long-chain polyunsaturated fatty acids is
associated with a decrease in fatty acid elongases Elovl2 and Elovl4.
Diabetes 59, 219–227
10. Tikhonenko, M., Lydic, T. A., Opreanu, M., Li Calzi, S., Bozack, S.,
McSorley, K. M., Sochacki, A. L., Faber, M. S., Hazra, S., Duclos, S.,
Guberski, D., Reid, G. E., Grant, M. B., and Busik, J. V. (2013) N-3
polyunsaturated Fatty acids prevent diabetic retinopathy by inhibition of
retinal vascular damage and enhanced endothelial progenitor cell repar-
ative function. PLoS One 8, e55177
11. Sala-Vila, A., Diaz-Lopez, A., Valls-Pedret, C., Cofan, M., Garcia-Layana,
A., Lamuela-Raventos, R. M., Castaner, O., Zanon-Moreno, V., Martinez-
Gonzalez, M. A., Toledo, E., Basora, J., Salas-Salvado, J., Corella, D.,
Gomez-Gracia, E., Fiol, M., et al. (2016) Dietary marine omega-3 fatty
acids and incident sight-threatening retinopathy in middle-aged and older
individuals with type 2 diabetes: Prospective investigation from the
PREDIMED trial. JAMA Ophthalmol. 134, 1142–1149
12. Majidi, S. P., and Rajagopal, R. (2020) Photoreceptor responses to light in
the pathogenesis of diabetic retinopathy. Vis. Neurosci. 37, E007
13. Shindou, H., Koso, H., Sasaki, J., Nakanishi, H., Sagara, H., Nakagawa, K.
M., Takahashi, Y., Hishikawa, D., Iizuka-Hishikawa, Y., Tokumasu, F.,
Noguchi, H., Watanabe, S., Sasaki, T., and Shimizu, T. (2017)
Docosahexaenoic acid preserves visual function by maintaining correct
disc morphology in retinal photoreceptor cells. J. Biol. Chem. 292, 12054–
12064
14. Kady, N. M., Liu, X., Lydic, T. A., Syed, M. H., Navitskaya, S., Wang, Q.,
Hammer, S. S., O’Reilly, S., Huang, C., Seregin, S. S., Amalfitano, A.,
Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Antonetti, D. A., et al.
(2018) ELOVL4-mediated production of very long-chain ceramides
Fatty acid synthase drives early diabetic retinopathy
12 J. Biol. Chem. (2021) 297(3) 101104
stabilizes tight junctions and prevents diabetes-induced retinal vascular
permeability. Diabetes 67, 769–781
15. Semenkovich, C. F. (1997) Regulation of fatty acid synthase (FAS). Prog.
Lipid Res. 36, 43–53
16. Rajagopal, R., Zhang, S., Wei, X., Doggett, T., Adak, S., Enright, J., Shah,
V., Ling, G., Chen, S., Yoshino, J., Hsu, F. F., and Semenkovich, C. F.
(2018) Retinal de novo lipogenesis coordinates neurotrophic signaling to
maintain vision. JCI Insight 3, e97076
17. Razani, B., Zhang, H., Schulze, P. C., Schilling, J. D., Verbsky, J., Lodhi, I.
J., Topkara, V. K., Feng, C., Coleman, T., Kovacs, A., Kelly, D. P., Saffitz, J.
E., Dorn, G. W., 2nd, Nichols, C. G., and Semenkovich, C. F. (2011) Fatty
acid synthase modulates homeostatic responses to myocardial stress. J.
Biol. Chem. 286, 30949–30961
18. Chakravarthy, M. V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J. G.,
Coleman, T., Turk, J., and Semenkovich, C. F. (2005) “New” hepatic fat
activates PPARalpha to maintain glucose, lipid, and cholesterol homeo-
stasis. Cell Metab. 1, 309–322
19. Wei, X., Song, H., Yin, L., Rizzo, M. G., Sidhu, R., Covey, D. F., Ory, D. S.,
and Semenkovich, C. F. (2016) Fatty acid synthesis configures the plasma
membrane for inflammation in diabetes. Nature 539, 294–298
20. Funai, K., Song, H., Yin, L., Lodhi, I. J.,Wei, X., Yoshino, J., Coleman, T., and
Semenkovich, C. F. (2013) Muscle lipogenesis balances insulin sensitivity
and strength through calcium signaling. J. Clin. Invest. 123, 1229–1240
21. Bogdanov, P., Corraliza, L., Villena, J. A., Carvalho, A. R., Garcia-Arumi,
J., Ramos, D., Ruberte, J., Simo, R., and Hernandez, C. (2014) The db/db
mouse: A useful model for the study of diabetic retinal neuro-
degeneration. PLoS One 9, e97302
22. Feit-Leichman, R. A., Kinouchi, R., Takeda, M., Fan, Z., Mohr, S., Kern,
T. S., and Chen, D. F. (2005) Vascular damage in a mouse model of
diabetic retinopathy: Relation to neuronal and glial changes. Invest.
Ophthalmol. Vis. Sci. 46, 4281–4287
23. Rajagopal, R., Bligard, G. W., Zhang, S., Yin, L., Lukasiewicz, P., and
Semenkovich, C. F. (2016) Functional deficits precede structural lesions in
mice with high-fat diet-induced diabetic retinopathy. Diabetes 65, 1072–
1084
24. Wakil, S. J., and Abu-Elheiga, L. A. (2009) Fatty acid metabolism: Target
for metabolic syndrome. J. Lipid Res. 50 Suppl, S138–143
25. Li, S., Chen, D., Sauve, Y., McCandless, J., Chen, Y. J., and Chen, C. K.
(2005) Rhodopsin-iCre transgenic mouse line for Cre-mediated rod-
specific gene targeting. Genesis 41, 73–80
26. Najmabadi, H., Hu, H., Garshasbi, M., Zemojtel, T., Abedini, S. S.,
Chen, W., Hosseini, M., Behjati, F., Haas, S., Jamali, P., Zecha, A.,
Mohseni, M., Puttmann, L., Vahid, L. N., Jensen, C., et al. (2011) Deep
sequencing reveals 50 novel genes for recessive cognitive disorders.
Nature 478, 57–63
27. Bowers, M., Liang, T., Gonzalez-Bohorquez, D., Zocher, S., Jaeger, B. N.,
Kovacs, W. J., Rohrl, C., Cramb, K. M. L., Winterer, J., Kruse, M.,
Dimitrieva, S., Overall, R. W., Wegleiter, T., Najmabadi, H.,
Semenkovich, C. F., et al. (2020) FASN-dependent lipid metabolism links
neurogenic stem/progenitor cell activity to learning and memory deficits.
Cell Stem Cell 27, 98–109.e11
28. Honasoge, A., Nudleman, E., Smith, M., and Rajagopal, R. (2019)
Emerging insights and interventions for diabetic retinopathy. Curr. Dia-
betes Rep. 19, 100
29. de Gooyer, T. E., Stevenson, K. A., Humphries, P., Simpson, D. A.,
Gardiner, T. A., and Stitt, A. W. (2006) Retinopathy is reduced during
experimental diabetes in a mouse model of outer retinal degeneration.
Invest. Ophthalmol. Vis. Sci. 47, 5561–5568
30. Liu, H., Tang, J., Du, Y., Lee, C. A., Golczak, M., Muthusamy, A.,
Antonetti, D. A., Veenstra, A. A., Amengual, J., von Lintig, J., Palczewski,
K., and Kern, T. S. (2015) Retinylamine benefits early diabetic retinopathy
in mice. J. Biol. Chem. 290, 21568–21579
31. Liu, H., Tang, J., Du, Y., Saadane, A., Samuels, I., Veenstra, A., Kiser, J. Z.,
Palczewski, K., and Kern, T. S. (2019) Transducin1, phototransduction
and the development of early diabetic retinopathy. Invest. Ophthalmol.
Vis. Sci. 60, 1538–1546
32. Thebeau, C., Zhang, S., Kolesnikov, A. V., Kefalov, V. J., Semenkovich, C.
F., and Rajagopal, R. (2020) Light deprivation reduces the severity of
experimental diabetic retinopathy. Neurobiol. Dis. 137, 104754
33. Okawa, H., Sampath, A. P., Laughlin, S. B., and Fain, G. L. (2008) ATP
consumption by mammalian rod photoreceptors in darkness and in light.
Curr. Biol. 18, 1917–1921
34. Pinot, M., Vanni, S., Pagnotta, S., Lacas-Gervais, S., Payet, L. A., Ferreira,
T., Gautier, R., Goud, B., Antonny, B., and Barelli, H. (2014) Lipid cell
biology. Polyunsaturated phospholipids facilitate membrane deformation
and fission by endocytic proteins. Science 345, 693–697
35. Chen, Y. F., Chen, H. Y., Lin, C. C., Chen, M. S., Chen, P. C., and Wang,
I. J. (2012) Retinitis pigmentosa reduces the risk of proliferative diabetic
retinopathy: A nationwide population-based cohort study. PLoS One 7,
e45189
36. Arden, G. B. (2001) The absence of diabetic retinopathy in patients with
retinitis pigmentosa: Implications for pathophysiology and possible
treatment. Br. J. Ophthalmol. 85, 366–370
37. Sternberg, P., Jr., Landers, M. B., 3rd, and Wolbarsht, M. (1984) The
negative coincidence of retinitis pigmentosa and proliferative diabetic
retinopathy. Am. J. Ophthalmol. 97, 788–789
38. Nippert, A. R., Biesecker, K. R., and Newman, E. A. (2018) Mecha-
nisms mediating functional hyperemia in the brain. Neuroscientist 24,
73–83
39. Rumora, A. E., LoGrasso, G., Hayes, J. M., Mendelson, F. E., Tabbey, M.
A., Haidar, J. A., Lentz, S. I., and Feldman, E. L. (2019) The divergent roles
of dietary saturated and monounsaturated fatty acids on nerve function in
murine models of obesity. J. Neurosci. 39, 3770–3781
40. Metea, M. R., and Newman, E. A. (2006) Glial cells dilate and constrict
blood vessels: A mechanism of neurovascular coupling. J. Neurosci. 26,
2862–2870
Fatty acid synthase drives early diabetic retinopathy
J. Biol. Chem. (2021) 297(3) 101104 13
